Ubl’s Successor At AdvaMed Will Struggle To Maintain User Fee Stability

AdvaMed Exec VP-Federal Government Relations Steve Ubl will be absent from the negotiating table July 15 when FDA meets with industry reps to discuss counterproposals to an 18% hike in 2005 user fee rates